pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
DUPIXENT · news · pharmadog
← back to DUPIXENT
News mentioning DUPIXENT
23
stories
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
9d
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
biopharma dive
10d
Regeneron backs $75M series A for antibody upstart Infinimmune
fiercebiotech
14d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
14d
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
15d
A COPD drug from China draws $115M in venture funding
biopharma dive
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
20d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
20d
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
20d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
endpoints
21d
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
21d
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
21d
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
27d
Sanofi halts development of troubled immune drug in eczema
biopharma dive
27d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
27d
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
endpoints
28d
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jun 10, 26
Sanofi stops immune drug trial in latest research setback
biopharma dive
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
